Decision: Favourable

Study Title:

TENECTEPLASE IN CENTRAL RETINAL ARTERY OCCLUSION STUDY (TenCRAOS): A Prospective, randomised-controlled, double-dummy, double-blind phase 3 multi-centre trial of TNK 0.25 mg/kg + placebo vs. ASA + placebo (2 arms with 1:1 block randomisation)

  • NREC Code:

    22-NREC-CT-009

  • Decision:

    Favourable

  • Meeting Date:

    27/04/2022

  • Study Type:

    CT application

  • Principal Investigator:

    Prof. Beatrice Nolan

  • PI Institution:

    CHI Crumlin

  • Sponsor:

    Sanofi

Scroll to Top